What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His main research concerns Prostate cancer, Prostate, Prostatectomy, Internal medicine and Cancer.
Peter R. Carroll studies Prostate-specific antigen, a branch of Prostate cancer.
His research in Prostate tackles topics such as Metastasis which are related to areas like Lymph node.
His research integrates issues of Hazard ratio, Androgen deprivation therapy, Nuclear medicine and Urology in his study of Prostatectomy.
His Internal medicine study typically links adjacent topics like Oncology.
His biological study deals with issues like Cancer research, which deal with fields such as DNA methylation.
His most cited work include:
- Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. (1542 citations)
- The Molecular Taxonomy of Primary Prostate Cancer (1426 citations)
- Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. (1314 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Prostate and Prostatectomy.
His study with Prostate cancer involves better knowledge in Cancer.
His studies in Cancer integrate themes in fields like Cancer research and Risk factor.
His Oncology study incorporates themes from Proportional hazards model, Metastasis and PCA3.
His Prostate research is multidisciplinary, incorporating elements of Adenocarcinoma, Magnetic resonance imaging, Radiology and Pathology.
His Prostatectomy research is multidisciplinary, incorporating perspectives in Stage, Radiation therapy, Surgery and Hazard ratio.
He most often published in these fields:
- Prostate cancer (66.78%)
- Internal medicine (45.22%)
- Oncology (35.76%)
What were the highlights of his more recent work (between 2016-2021)?
- Prostate cancer (66.78%)
- Internal medicine (45.22%)
- Oncology (35.76%)
In recent papers he was focusing on the following fields of study:
Peter R. Carroll spends much of his time researching Prostate cancer, Internal medicine, Oncology, Prostate and Prostatectomy.
His Prostate cancer research is multidisciplinary, relying on both Biopsy and Radiology.
His biological study spans a wide range of topics, including Recurrent prostate cancer, Androgen deprivation therapy, Metastasis, Gene and Localized disease.
The concepts of his Prostate study are interwoven with issues in Surveillance study, Interquartile range, Confidence interval and Urology.
His Prostatectomy research includes elements of Biomarker, Nuclear medicine and Lymph node.
His Cancer research incorporates elements of Cancer research and Gynecology.
Between 2016 and 2021, his most popular works were:
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy (296 citations)
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial (154 citations)
- Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060)) (147 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
Peter R. Carroll focuses on Prostate cancer, Internal medicine, Prostate, Oncology and Prostatectomy.
His Prostate cancer study is associated with Cancer.
His studies in Internal medicine integrate themes in fields like PET-CT and Surgery.
He interconnects Urology, Retrospective cohort study, Magnetic resonance imaging, Radiology and Prospective cohort study in the investigation of issues within Prostate.
Peter R. Carroll has included themes like Odds ratio, Androgen deprivation therapy, Metastasis, Disease and Gene in his Oncology study.
His studies deal with areas such as Interquartile range and Nuclear medicine as well as Prostatectomy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
